Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | BLK | P51451 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19972696 | 0.85 | GPR119 (0.49) | GPR119PIK3CAMTORPRKDCLYN | |
| SCHEMBL2251051 | 0.82 | GPR119 (0.46) | GPR119PIK3CAMTORPRKDC | |
| SCHEMBL22043738 | 0.80 | GPR119 (0.45) | GPR119PIK3CAMTORPRKDCLYN | |
| SCHEMBL8111309 | 0.79 | ALDH1A1 (0.57) | — | |
| SCHEMBL19972609 | 0.79 | BLK (0.54) | GPR119LYNBLKBTK | |
| SCHEMBL8103415 | 0.79 | OPRL1 (0.53) | GPR119 | |
| SCHEMBL20598891 | 0.78 | CYP3A4 (0.41) | GPR119CYP3A4CYP2D6BTK | |
| SCHEMBL2247700 | 0.76 | CCR5 (0.51) | GPR119CYP3A4 | |
| SCHEMBL12357645 | 0.75 | ALDH1A1 (0.49) | GPR119PIK3CAMTORPRKDC | |
| SCHEMBL2250127 | 0.75 | ALDH1A1 (0.47) | GPR119PIK3CAMTORPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190336-A1 | AZABENZIMIDAZOLONES | CARA THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190336-A1 | AZABENZIMIDAZOLONES | CARA THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190336-A1 | AZABENZIMIDAZOLONES | CARA THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010045276-A2 | AZABENZIMIDAZOLONES | CARA THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045276-A2 | AZABENZIMIDAZOLONES | CARA THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190336-A1 | AZABENZIMIDAZOLONES | PTGER1, PTGDR, PTGER2 | GPR119 569/4885PIK3CA 2616/4885MTOR 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.